Table 3.

Results of survival analysis

CharacteristicMedian PFS (95% CI, wk)PHazard ratio (95% CI)PMedian OS (95% CI, wk)PHazard ratio (95% CI)P
Age (y)
    ≤6011.1 (7.4-19.0)0.98730.9 (21.6-55.3)0.610
    >6012.0 (6.9-19.0)30.0 (17.4-46.0)
Sex
    Male10.1 (6.9-16.6)0.42725.3 (19.0-36.7)0.305
    Female13.0 (6.9-38.0)43.6 (25.6-102.0)
Stage
    IIIB7.6 (2.4-15.4)0.10520.4 (8.7-31.0)0.120
    IV12.0 (8.3-20.4)32.9 (22.0-56.6)
Smoking history
    Never25.6 (9.6-38.0)0.002Reference0.01246.0 (25.6-85.4)0.043Reference0.046
    Ever8.6 (4.7-12.3)1.9 (1.2-3.2)22.0 (15.3-30.9)1.9 (1.0-3.4)
Histopathology
    Adenocarcinoma18.0 (9.6-29.4)0.003Reference0.06137.6 (21.6-85.4)0.009Reference0.045
    Other8.1 (4.7-13.0)1.7 (1.0-2.9)21.9 (12.1-31.0)1.9 (1.0-3.7)
Performance status
    0-113.3 (8.6-20.4)0.175Reference0.06754.1 (26.1-85.4)0.002Reference<0.001
    2-38.6 (6.3-16.0)1.6 (1.0-2.5)18.3 (10.4-28.6)3.3 (1.8-5.8)
Prior treatment
    No15.4 (>4.7)0.51128.6 (>12.1)0.911
    Yes11.1 (7.6-16.6)30.9 (21.6-43.6)
SUV
    Low (<6.2)33.1 (13.0-58.9)0.003Reference0.01260.4 (29.1-128.9)0.011Reference0.043
    High (≥6.2)8.6 (6.7-13.0)2.3 (1.2-4.5)21.9 (17.4-32.9)2.2 (1.0-4.5)